Cambridge Investment Research Advisors, Inc. Aim Immuno Tech Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$27.1 Billion
Q2 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$0.32 - $0.77 $8,428 - $20,281	-26,339 Reduced 56.43%	20,340 $9,000
Q4 2022 Feb 08, 2023	SELL	$0.31 - $0.6 $154 - $299	-499 Reduced 1.06%	46,679 $15,000
Q3 2022 Oct 17, 2022	BUY	$0.57 - $0.81 $285 - $405	500 Added 1.07%	47,178 $0
Q1 2022 May 12, 2022	BUY	$0.67 - $1.18 $31,274 - $55,080	46,678 New	46,678 $49,000
Q4 2021 Feb 03, 2022	SELL	$0.92 - $1.96 $42,944 - $91,490	-46,679 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$1.88 - $2.82 $11,280 - $16,920	6,000 Added 14.75%	46,679 $105,000
Q4 2020 Feb 04, 2021	BUY	$1.68 - $2.45 $10,920 - $15,925	6,500 Added 19.02%	40,679 $72,000
Q3 2020 Oct 29, 2020	BUY	$1.77 - $3.88 $60,496 - $132,614	34,179 New	34,179 $73,000

Others Institutions Holding AIM

# of Institutions

Shares Held

8.44M

Call Options Held

Put Options Held

Armistice Capital, LLC New York, NY

4.08M
Shares

$1.02 Million
0.02% of portfolio
Vanguard Group Inc Valley Forge, PA

1.99M
Shares

$497,176
0.0% of portfolio
Black Rock Inc. New York, NY

698K
Shares

$174,566
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

401K
Shares

$100,256
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

229K
Shares

$57,202
0.0% of portfolio

View Full List

About AIM ImmunoTech Inc.

Ticker AIM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,049,300
Market Cap $12M
Description
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome...

More about AIM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account